Abstract
Prostate cancer is the second most frequent cancer in men. The frequency of the prostate cancer is greatly varies in different populations of the world. Three common polymorphisms in promoter region of interleukin-10 (IL-10) gene viz. -1082 A>G, -819 C>T and -592 C>A are extensively studied in prostate cancer with inconclusive results. So, a meta-analysis was performed to assess the association between these three IL-10 gene polymorphisms and risk of prostate cancer susceptibility. Suitable studies were retrieved by electronic databases search and odds ratios (ORs) with 95% confidence intervals (CIs) were used as association measure. All the statistical analyses were conducted in the Open Meta-Analyst program.
In our meta-analysis we included 17 studies (10,718 samples), 11 studies (8,391 samples) and 13 studies (7,801 samples) for -1082 A>G, -819 C>T and -592 C>A polymorphisms respectively. The result of the -592 C>A polymorphism revealed low heterogeneity with no association in the overall analysis (ORAvs.C= 1.05, 95% CI= 0.99-1.12, p= 0.09, I2= 35.89%). In ethnicity based stratified analyses, significant association was found in Caucasian population with prostate cancer using allele contrast model (ORAvs.C= 1.08, 95% CI= 1.01-1.16, p= 0.02, I2= 19.37%), homozygote model (ORAAvs.CC= 1.24, 95% CI= 1.00-1.52, p= 0.04, I2= 0%), and dominant model (ORAA+CAvs.CC= 1.10, 95% CI= 1.00-1.22, p= 0.05, I2= 32.57%). No such results were found in the Asian population. In the other two polymorphisms i.e. -1082 A>G and -819 C>T, no significant association with prostate cancer was observed.
In conclusion, results of present meta-analysis suggested that IL-10 -592 C>A polymorphism plays a role in the progression of the prostate cancer in the Caucasian population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The article does not contain any studies with human or animal subjects performed by any of the authors.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data is given in the manuscript.